Innovations in the Therapy of Atopic Dermatitis Complicated by a Secondary Infection
https://doi.org/10.15690/pf.v15i4.1946
Abstract
Reduced skin barrier properties in patients with atopic dermatitis (AtD) are largely caused by microbiome changes and extensive Staphylococcus aureus colonisation of the skin. In this regard, the integument of patients with AtD requires constant care and the use of various emollients. The inclusion of lysates of non-pathogenic microorganisms and prebiotics in the composition of emollients ensures the normalisation of the microbiome composition and the immunological barrier of the skin. The article presents the results of our own observations on the application of two cosmetic scin-care products for damaged skin with vitamin F in children with AtD complicated by a secondary infection, while the composition of one of the products is additionally enriched with ceramides and prebiotics. The safety and high efficacy of both products have been shown, however, the presence of ceramides and prebiotics in the emollient composition makes it possible to achieve a marked decrease in the degree of S. aureus colonisation of the skin.
About the Authors
Nikolay N. MurashkinRussian Federation
Alexander I. Materikin
Russian Federation
Eduard T. Ambarchian
Russian Federation
Roman V. Epishev
Russian Federation
Dmitriy V. Fedorov
Russian Federation
References
1. Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116–132. doi: 10.1016/j.jaad. 2014.03.023.
2. Baron SE, Cohen SN, Archer CB, et al. Guidance on the diagnosis and clinical management of atopic eczema. Clin Exp Dermatol. 2012;37 Suppl 1:7–12. doi: 10.1111/j.1365-2230.2012.04336.x.
3. Williams H, Flohr C. How epidemiology has challenged 3 prevailing concepts about atopic dermatitis. J Allergy Clin Immunol. 2006;118(1):209–213. doi: 10.1016/j.jaci.2006.04.043.
4. Williams HC. Clinical practice. Atopic dermatitis. N Engl J Med. 2005;352(22):2314–2324. doi: 10.1056/NEJMcp042803.
5. Bieber T. Atopic dermatitis 2.0: from the clinical phenotype to the molecular taxonomy and stratified medicine. Allergy. 2012; 67(12):1475–1482. doi: 10.1111/all.12049.
6. Jordan HF, Todd G, Sinclair W, Green RJ. Aetiopathogenesis of atopic dermatitis. S Afr Med J. 2014;104(10):706–709. doi: 10.7196/samj.8840.
7. Aberg KM, Man MQ, Gallo RL, et al. Co-regulation and interdependence of the mammalian epidermal permeability and antiСПИСОК ЛИТЕРАТУРЫ microbial barriers. J Invest Dermatol. 2008;128(4):917–925. doi: 10.1038/sj.jid.5701099.
8. Biedermann T. Dissecting the role of infections in atopic dermatitis. Acta Derm Venereol. 2006;86(2):99–109. doi: 10.2340/ 00015555-0047.
9. Breuer K, Wittmann M, Bosche B, et al. Severe atopic dermatitis is associated with sensitization to Staphylococcal enterotoxin B (SEB). Allergy. 2000;55(6):551–555. doi: 10.1034/j.1398- 9995.2000.00432.x.
10. Leung DY, Guttman-Yassky E. Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches. J Allergy Clin Immunol. 2014;134(4):769–779. doi: 10.1016/j. jaci.2014.08.008.
11. De Benedetto A, Agnihothri R, McGirt LY, et al. Atopic Dermatitis: a disease caused by innate immune defects? J Invest Dermatol. 2009;129(1):14–30. doi: 10.1038/jid.2008.259.
12. Niebuhr M, Werfel T. Innate immunity, allergy and atopic dermatitis. Curr Opin Allergy Clin Immunol. 2010;10(5):463–468. doi: 10.1097/ACI.0b013e32833e3163.
13. Кудрявцева А.В., Катосова Л.К., Балаболкин И.П., Асеева В.Г. Роль золотистого стафилококка при атопическом дерматите у детей. Педиатрия. Журнал им. Г.Н. Сперанского. — 2003. — Т.82. — №6 — С. 32–36. [Kudryavtseva AV, Katosova LK, Balabolkin II, Aseeva VG. Role of Staphylococcus aureus in pediatric atopic dermatitis. Pediatriia. 2003;82(6):32–36. (In Russ).]
14. Kedzierska A, Kapinska-Mrowiecka M, Czubak-Macugowska M, et al. Susceptibility testing and resistance phenotype detection in Staphylococcus aureus strains isolated from patients with atopic dermatitis, with apparent and recurrent skin colonization. Br J Dermatol. 2008;159(6):1290–1299. doi: 10.1111/j.1365- 2133.2008.08817.x.
15. Pinchuk IV, Beswick EJ, Reyes VE. Staphylococcal enterotoxins. Toxins (Basel). 2010;2(8):2177–2197. doi: 10.3390/toxins2082177.
16. Pastuszka M, Matych M, Kaszuba A, et al. Microorganisms in the etiopathogenesis of atopic dermatitis. Postep Derm Alergol. 2012;29(3):215–221.
17. Boguniewicz M, Leung DY. Recent insights into atopic dermatitis and implications for management of infectious complications. J Allergy Clin Immunol. 2010;125(1):4–13. doi: 10.1016/j. jaci.2009.11.027.
18. Ng JP, Liew HM, Ang SB. Use of emollients in atopic dermatitis. J Eur Acad Dermatol Venereol. 2015;29(5):854–857. doi: 10.1111/ jdv.12864.
19. Намазова-Баранова Л.С., Баранов А.А., Кубанова А.А., и др. Атопический дерматит у детей: современные клинические рекомендации по диагностике и терапии // Вопросы современной педиатрии. — 2016. — Т.15. — №3 — С. 279–294. [Namazova-Baranova LS, Baranov AA, Kubanova AA, et al. Atopic Dermatitis in Children: Current Clinical Guidelines for Diagnosis and Therapy. Current pediatrics. 2016;15(3):279–294. (In Russ).] doi: 10.15690/vsp.v15i3.1566.
20. Мурашкин Н.Н., Глузмин М.И., Материкин А.И., Хотко А.А. Корнеотерапия как метод коррекции эпидермальных нарушений при хронических дерматозах у детей // Эффективная фармакотерапия. — 2012. — №31 — С. 26–31. [Murashkin NN, Gluzmin MI, Materikin AI, Khotko AA. Korneoterapiya kak metod korrektsii epidermal'nykh narushenii pri khronicheskikh dermatozakh u detei. Effektivnaya farmakoterapiya. 2012;(31):26–31. (In Russ).]
21. Boisnic S, Branchet-Gumila MC, Segard C. Inhibitory effect of Avene spring water on vasoactive intestinal peptide-induced inflammation in surviving human skin. Int J Tissue React. 2001;23(3):89–95.
Review
For citations:
Murashkin N.N., Materikin A.I., Ambarchian E.T., Epishev R.V., Fedorov D.V. Innovations in the Therapy of Atopic Dermatitis Complicated by a Secondary Infection. Pediatric pharmacology. 2018;15(4):318-323. (In Russ.) https://doi.org/10.15690/pf.v15i4.1946